What's New
News
- 2025年09月25日
- Annual update has been made to our Sustainability site.
- 2025年09月19日
- Nippon Kayaku announces IBTROZIRCapsules 200mg (taletrectinib) has been approved in Japan for patients with unresectable advanced and/or recurrent ROS1-positive non-small cell lung cancer
- 2025年08月25日
- Announcement of Joint Venture Establishment and Shareholders Agreement Execution
- 2025年07月09日
- Nippon Kayaku Selected as a Constituent of all ESG Indices by GPIF
- 2025年06月12日
- Nippon Kayaku announces IBTROZITM approved in the U.S. for patients with advanced ROS1-positive Non-Small Cell Lung Cancer
- 2025年06月02日
- Presentation of new data from pivotal phase II clinical studies of taletrectinib, a novel ROS1 inhibitor, in patients with advanced ROS1-positive Non-Small Lung Cancer at ASCO 2025
- 2025年05月30日
- Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
- 2025年05月08日
- Nippon Kayaku received MSCI ESG Ratings of AA for the second year
- 2025年03月03日
- Nippon Kayaku announces completion of marketing authorization application of a novel ROS1 inhibitor, taletrectinib, for use in patients with advanced ROS1-positive Non-Small Cell Lung Cancer in Japan
- 2025年01月07日
- Nippon Kayaku Selected as constituent of FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index
- 2024年11月01日
- Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advanced ROS1-positive Non-Small Cell Lung Cancer.
- 2024年10月10日
- Annual update has been made to our Sustainability site.
- 2024年05月08日
- Received ‘AA’ for the first time in MSCI ESG Ratings
- 2023年12月15日
- NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
- 2023年10月19日
- Updated information of sustainability
- 2023年10月18日
- Trastuzumab BS for I.V. Infusion 60mg "NK"・150mg "NK" Obtained Approval for Additional Indication
- 2023年09月25日
- Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody. PDF
- 2022年11月16日
- Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg "CTNK" ,an anti-VEGF humanized monoclonal antibody PDF
- 2021年06月30日
- New Late-Breaking Data at The American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 Severity PDF
- 2020年07月06日
- Pict Leap Co., Ltd has developed " Liquid Crystal Display Which Can Be Photographed By Infrared Camera " PDF